Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Neurogastroenterology and motility
- Publicado em
- 30 set 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
Jan Tack, Borislav Vladimirov, Ivo Horny, Chui Fung Chong, Jessica Eisner, Richard Czerniak, Yohei Takanami
Descritores MeSH
- Gastroesophageal Reflux
- Esomeprazole
- Heartburn
- Humans
- Double-Blind Method
- Pyrroles
- Sulfonamides
- Treatment Outcome
- Proton Pump Inhibitors
- Middle Aged